№ lp_1_2_21295
File format: docx Character count: 106359 File size: 508 KB
Year: 2024
Region / city: Global
Theme: Oncology, Endometrial Cancer, Pharmaceutical Submissions
Document Type: Medical Submission
Organization / Institution: AstraZeneca Pty Ltd
Author: AstraZeneca Pty Ltd
Target Audience: Medical professionals, regulatory bodies, pharmaceutical companies
Period of validity: Not specified
Approval Date: Not specified
Modification Date: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Public Summary of PBAC Resubmission for Dostarlimab (Jemperli) in Recurrent or Advanced dMMR Endometrial Cancer, November 2022
Year: 2022
Country: Australia
Therapeutic area: Oncology
Disease: Endometrial cancer
Biomarker status: Mismatch repair deficient (dMMR)
Medicine name: Dostarlimab
Brand name: Jemperli
Dosage form: Solution concentrate for intravenous infusion
Sponsor: GlaxoSmithKline Australia Pty Ltd
Regulatory body: Pharmaceutical Benefits Advisory Committee
Submission type: Standard Re-entry submission
Requested listing: Section 100
Comparator treatments: Standard of care chemotherapy; pembrolizumab plus lenvatinib; pembrolizumab monotherapy
Clinical trial referenced: GARNET
Approval status: Provisional approval
Indication: Recurrent or advanced endometrial cancer after platinum-containing regimen
Decision context: PBS listing consideration
Period covered: Up to November 2022
Supplementary Table 1. Characterization of endometrial cancer cell lines.
Year: n.d.
Region / city: n.d.
Topic: Cancer research
Document type: Supplementary table
Organization / institution: n.d.
Author: n.d.
Target audience: Researchers, medical professionals
Effective period: n.d.
Approval date: n.d.
Amendment date: n.d.
Sentinel Consensus Document for Vulval, Endometrial and Cervical Cancer, BGCS, January 2019
Year: 2019
Month: January
Organisation: British Gynaecological Cancer Society (BGCS)
Region: United Kingdom
Field: Gynaecological Oncology
Topic: Sentinel Lymph Node Technique in Vulval, Cervical and Endometrial Cancer
Document Type: Consensus Statement
Authors: Christina Fotopoulou; Thomas Ind; Peter Baldwin; Robin Crawford; Omer Devaja; Stephen Dobbs; Jonathan Frost; Ketan Gajjar; Raji Ganesan; Sonali Kaushik; Jo Morrison; Marielle Nobbenhuis; Nithya Ratnavelu; Phil Rolland; Naveena Singh; Alexandra Taylor; Sudha Sundar; Andy Nordin
Participating Body: BGCS officers and expert members of the UK gynaecological oncological community
Methodology: Delphi process with two rounds and 80% consensus threshold
Scope: Applicability, oncologic safety and surgical safety of sentinel lymph node algorithms
Cancers Addressed: Vulval cancer; Cervical cancer; Endometrial cancer
Guidelines Considered: European Society of Gynaecological Oncologists (ESGO)
Implementation Context: UK gynaecological cancer centres
Clinical Focus: Surgical staging; SLN mapping; Lymphadenectomy; Histological ultra-staging; Training and audit requirements
APPLICATION FORMESGO Accreditation of Endometrial Cancer Surgery
Year: 2023
Region / City: N/A
Subject: Endometrial Cancer Surgery Accreditation
Document Type: Application Form
Organization / Institution: ESGO
Author: N/A
Target Audience: Medical centers, healthcare professionals
Period of validity: N/A
Approval Date: N/A
Date of changes: N/A
Supplementary Figure Legends of EpCAM and LEF1 Expression in Endometrial Cancer Studies
Year: 2026
Region / City: Not specified
Subject: Molecular and cellular analysis of endometrial cancer
Document Type: Supplementary figures
Institution: Not specified
Authors: Not specified
Target Audience: Researchers in oncology and molecular biology
Study Period: Not specified
Data Sources: Human endometrial cancer patients, cancer cell lines, mouse endometrial tissues, TCGA database
Methods: Immunohistochemistry, immunofluorescence, ChIP-seq, RT-qPCR, AFM
Measured Parameters: Gene expression, cell migration, apoptosis, cytoskeleton content, adhesion force
Statistical Significance Indicators: * P<0.05, ** P<0.01, *** P<0.005, **** P<0.001
Service Specification for Endometrial Biopsy
Year: 2017-2018
Region / city: Doncaster
Subject: Gynaecology, Endometrial Biopsy
Document Type: Service Specification
Organization: NHS Doncaster CCG
Author: Not specified
Target Audience: Healthcare providers, GPs
Effective Period: 1st April 2017 to 31st March 2018
Approval Date: Not specified
Date of Last Review: Annual
Changes Date: Not specified
Topics: durvalumab olaparib endometrial